| Sep 6 |
Pandemic Darling Moderna Needs a Reality Check
|
| Sep 5 |
Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?
|
| Sep 5 |
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
|
| Sep 4 |
Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript
|
| Sep 4 |
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
|
| Sep 4 |
High-dose Spinraza meets study goal; Top Dyne executives exit
|
| Sep 4 |
Biogen announces trial win for higher Spinraza doze
|
| Sep 4 |
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
|
| Sep 3 |
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
|
| Aug 27 |
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
|
